| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [D. R. S., C. A. P., C. F. G., A. P.] and Medicine [D. G. T.], Beth Israel Hospital and Harvard Medical School, and the Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215
We have previously demonstrated that a wide variety of rodent and human tumor cells secrete markedly elevated levels of a transformation-related phosphoprotein with a molecular weight (depending on animal species) of 58,000 to 69,000. With antibody raised to the tumor-secreted phosphoprotein (rat), we have now identified an antigenically related protein in normal rat and human plasma. The rat plasma protein and the rat tumor-secreted phosphoproteins comigrated on polyacrylamide gels and were identically cleaved during blood coagulation as well as by purified thrombin. Mouse macrophages expressed a similar or identical phosphoprotein suggesting that monocytic cells may be a source of the normal plasma protein. Consistent with elevated secretion of this protein by tumor cells, plasma and sera from cancer patients contained elevated levels of this protein, raising the possibility that this circulating marker may prove useful for monitoring tumor burden. Amino acid sequence derived from the amino terminus of the rat tumor phosphoprotein indicates that it is distinct from previously sequenced proteins, but that it may be related to protein-tyrosine kinases encoded by viral and proto-onc genes.
1 This investigation was supported by USPHS Grant CA 34025 (to D. R. S.) awarded by the National Cancer Institute, Department of Health and Human Services. Grant 1 U41 RR-0 1685-05 to the BIONET national computer resource made database searches possible.
2 To whom requests for reprints should be addressed, at the Department of Pathology, Beth Israel Hospital, 330 Brookline Avenue, Boston, MA 02215.
Received 2/24/88. Revised 7/ 6/88. Accepted 7/14/88.
This article has been cited by other articles:
|
|
 |
|
  L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Lee, M.-J. Wang, P.-R. Sudhir, G.-D. Chen, C.-W. Chi, and J.-Y. Chen Osteopontin Promotes Integrin Activation through Outside-In and Inside-Out Mechanisms: OPN-CD44V Interaction Enhances Survival in Gastrointestinal Cancer Cells Cancer Res., March 1, 2007; 67(5): 2089 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gao, H. Guo, Z. Mi, M. J. Grusby, and P. C. Kuo Osteopontin Induces Ubiquitin-Dependent Degradation of STAT1 in RAW264.7 Murine Macrophages J. Immunol., February 1, 2007; 178(3): 1870 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. El-Tanani, F. C. Campbell, P. Crowe, P. Erwin, D. P. Harkin, P. Pharoah, B. Ponder, and P. S. Rudland BRCA1 Suppresses Osteopontin-mediated Breast Cancer J. Biol. Chem., September 8, 2006; 281(36): 26587 - 26601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mi, H. Guo, P. Y. Wai, C. Gao, and P. C. Kuo Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells Carcinogenesis, June 1, 2006; 27(6): 1134 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. H.C. Bramwell, G. S. Doig, A. B. Tuck, S. M. Wilson, K. S. Tonkin, A. Tomiak, F. Perera, T. A. Vandenberg, and A. F. Chambers Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3337 - 3343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jang, T. Savarese, H. P. Low, S. Kim, H. Vogel, D. Lapointe, T. Duong, N. S. Litofsky, J. M. Weimann, A. H. Ross, et al. Osteopontin Expression in Intratumoral Astrocytes Marks Tumor Progression in Gliomas Induced by Prenatal Exposure to N-Ethyl-N-Nitrosourea Am. J. Pathol., May 1, 2006; 168(5): 1676 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Maeno, S. Nakazawa, N. Yamamoto, M. Shinzato, S. Nagashima, K. Tanaka, J. Sasaki, S. R. Rittling, D. T. Denhardt, T. Uede, et al. Osteopontin Participates in Th1-Mediated Host Resistance against Nonlethal Malaria Parasite Plasmodium chabaudi chabaudi Infection in Mice Infect. Immun., April 1, 2006; 74(4): 2423 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Hickey, K. England, and T. G. Cotter Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK J. Leukoc. Biol., July 1, 2005; 78(1): 289 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Mi, H. Guo, P. Y. Wai, C. Gao, J. Wei, and P. C. Kuo Differential Osteopontin Expression in Phenotypically Distinct Subclones of Murine Breast Cancer Cells Mediates Metastatic Behavior J. Biol. Chem., November 5, 2004; 279(45): 46659 - 46667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. El-Tanani, A. Platt-Higgins, P. S. Rudland, and F. C. Campbell Ets Gene PEA3 Cooperates with {beta}-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin Transcription J. Biol. Chem., May 14, 2004; 279(20): 20794 - 20806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Coppola, M. Szabo, D. Boulware, P. Muraca, M. Alsarraj, A. F. Chambers, and T. J. Yeatman Correlation of Osteopontin Protein Expression and Pathological Stage across a Wide Variety of Tumor Histologies Clin. Cancer Res., January 1, 2004; 10(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Myles, T. Nishimura, T. H. Yun, M. Nagashima, J. Morser, A. J. Patterson, R. G. Pearl, and L. L. K. Leung Thrombin Activatable Fibrinolysis Inhibitor, a Potential Regulator of Vascular Inflammation J. Biol. Chem., December 19, 2003; 278(51): 51059 - 51067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Chang, M. Cao, and P. Hicks Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells Carcinogenesis, November 1, 2003; 24(11): 1749 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Denhardt Commentary re: Q-T. Le et al., Identification of Osteopontin as a Prognostic Marker for Head and Neck Squamous Cell Carcinomas. Clin. Cancer Res., 9: 31-32, 2003. Clin. Cancer Res., January 1, 2003; 9(1): 31 - 32. [Full Text] [PDF]
|
|
|
|
|
|
P. S. Rudland, A. Platt-Higgins, M. El-Tanani, S. de Silva Rudland, R. Barraclough, J. H. R. Winstanley, R. Howitt, and C. R. West Prognostic Significance of the Metastasis-associated Protein Osteopontin in Human Breast Cancer Cancer Res., June 1, 2002; 62(12): 3417 - 3427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Urquidi, D. Sloan, K. Kawai, D. Agarwal, A. C. Woodman, D. Tarin, and S. Goodison Contrasting Expression of Thrombospondin-1 and Osteopontin Correlates with Absence or Presence of Metastatic Phenotype in an Isogenic Model of Spontaneous Human Breast Cancer Metastasis Clin. Cancer Res., January 1, 2002; 8(1): 61 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-H. Lin and H.-F. Yang-Yen The Osteopontin-CD44 Survival Signal Involves Activation of the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway J. Biol. Chem., November 30, 2001; 276(49): 46024 - 46030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H. N. Wong, A. T. Chan, and P. J. Johnson Quantitative Analysis of Circulating Tumor Cells in Peripheral Blood of Osteosarcoma Patients Using Osteoblast-specific Messenger RNA Markers: A Pilot Study Clin. Cancer Res., June 1, 2000; 6(6): 2183 - 2188. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.-H. Lin, C.-J. Huang, J.-R. Chao, S.-T. Chen, S.-F. Lee, J. J.-Y. Yen, and H.-F. Yang-Yen Coupling of Osteopontin and Its Cell Surface Receptor CD44 to the Cell Survival Response Elicited by Interleukin-3 or Granulocyte-Macrophage Colony-Stimulating Factor Mol. Cell. Biol., April 15, 2000; 20(8): 2734 - 2742. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Yokosaki, N. Matsuura, T. Sasaki, I. Murakami, H. Schneider, S. Higashiyama, Y. Saitoh, M. Yamakido, Y. Taooka, and D. Sheppard The Integrin alpha 9beta 1 Binds to a Novel Recognition Sequence (SVVYGLR) in the Thrombin-cleaved Amino-terminal Fragment of Osteopontin J. Biol. Chem., December 17, 1999; 274(51): 36328 - 36334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Thalmann, R. A. Sikes, R. E. Devoll, J. A. Kiefer, R. Markwalder, I. Klima, C. M. Farach-Carson, U. E. Studer, and L. W. K. Chung Osteopontin: Possible Role in Prostate Cancer Progression Clin. Cancer Res., August 1, 1999; 5(8): 2271 - 2277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Q. Yu, J.-M. Fan, D. J. Nikolic-Paterson, N. Yang, W. Mu, R. Pichler, R. J. Johnson, R. C. Atkins, and H. Y. Lan IL-1 Up-Regulates Osteopontin Expression in Experimental Crescentic Glomerulonephritis in the Rat Am. J. Pathol., March 1, 1999; 154(3): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Safran, W. T. Butler, and M. C. Farach-Carson Modulation of Osteopontin Post-translational State by 1,25-(OH)2-Vitamin D3. DEPENDENCE ON Ca2+ INFLUX J. Biol. Chem., November 6, 1998; 273(45): 29935 - 29941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Panda, G. C. Kundu, B. I. Lee, A. Peri, D. Fohl, I. Chackalaparampil, B. B. Mukherjee, X. D. Li, D. C. Mukherjee, S. Seides, et al. Potential roles of osteopontin and alpha Vbeta 3 integrin in the development of coronary artery restenosis after angioplasty PNAS, August 19, 1997; 94(17): 9308 - 9313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Beck Jr., B. Zerler, and E. Moran Phosphate is a specific signal for induction of osteopontin gene expression PNAS, July 18, 2000; 97(15): 8352 - 8357. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
